SavedAdd your journal

Journals / ANKEM Dergisi / 2006 / Cilt: 20 - Sayı: 4

In-vitro activities of tigecycline in Klebsiella pneumoniae strains isolated from clinical specimens

Klinik örneklerden soyutlanan Klebsiella pneumoniae suşlarında tigesikliğinin in-vitro aktivitesi

UĞUR ARSLAN
Ferhat IŞIK
İnci TUNCER
Pages
199–201
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

All isolates were found susceptible to tigecycline.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tigecycline (GAR-936), a new glycylcycline antibiotic, has shown promising in-vitro activity against many common pathogens including multidrug resistant strains.
📊
Key Findings & Data:In this study, the in-vitro activities of tigecycline against 100 Klebsiella pneumoniae (50 extended-spectrum beta-lactamase positive and 50 negative) strains isolated from clinical specimens were examined.
💡
Conclusion & Impact:All isolates were found susceptible to tigecycline.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:In vitro · beta-Laktamazlar · Klebsiella pneumoniae

Abstract

Tigecycline (GAR-936), a new glycylcycline antibiotic, has shown promising in-vitro activity against many common pathogens including multidrug resistant strains. In this study, the in-vitro activities of tigecycline against 100 Klebsiella pneumoniae (50 extended-spectrum beta-lactamase positive and 50 negative) strains isolated from clinical specimens were examined. MIC values of tigecycline were determined by E-test method. MIC50 and MIC90 results of tigecycline against extended spectrum beta-lactamase positive and negative K.pneumoniae isolates were 0.38-1 µg/ml and 0.25 -0.5 µg/ml, respectively. All isolates were found susceptible to tigecycline.

Özet

Yeni bir glisilsiklin antibiyotik olan tigesiklin (GAR-936), çoğul ilaç dirençli türlerin de bulunduğu bir çok yaygın patojene karşı in-vitro etkili görünmektedir. Bu çalışmada, klinik örneklerden soyutlanan 50’si genişlemiş spektrumlu beta-laktamaz pozitif, 50’si negatif olan 100 Klebsiella pneumoniae suşuna karşı tigesiklinin in-vitro aktivitesi araştırılmıştır. Tigesiklin için MİK değerleri E-test metodu ile belirlenmiştir. Genişlemiş spektrumlu beta-laktamaz pozitif ve negatif K.pneumoniae suşları için tigesiklinin MİK50 ve MİK90 değerleri sırası ile 0.38-1 µg/ml ve 0.25-0.5 µg/ml olarak saptanmıştır. Suşların tümü tigesikline duyarlı bulunmuştur.

🔖

Cite This Article

ARSLAN, U., IŞIK, F., TUNCER, İ. (2006). In-vitro activities of tigecycline in Klebsiella pneumoniae strains isolated from clinical specimens. ANKEM Dergisi, Cilt: 20 - Sayı: 4, 199–201. https://ajindex.com/articles/355078

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Betriu C, Rodriguez-Avial I, Sanchez BA et al: In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain, Antimicrob Agents Chemother 2002;46(3):892-5
  2. Biedenbach DJ, Beach ML, Jones RN: In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases, Diagn Microbiol Infect Dis 2001;40(4):173-7
  3. Bouchillon SK, Hoban DJ, Johnson HB et al: In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002, Diagn Microbiol Infect Dis 2005;51(4):291-5
  4. Clinical and Laboratory Standards Institute (CLSI) (Gür D: Çeviri editörü): Antimikrobik Duyarlılık Testleri İçin Uygulama Standartları, Onbeşinci Bilgi Eki. M100-S14, Bilimsel Tıp Yayınevi, Ankara (2005)
  5. Çetinkaya Z, Çiftçi İH, Aktepe OC, Şafak B, Altındiş M: Klinik örneklerden izole edilen Klebsiella izolatlarının antibiyotiklere duyarlılıkları, ANKEM Derg 2005;19(1):1-4
  6. Dolapçı İ: Genişlemiş spektrumlu bata laktamazlar: Klinik mikrobiyoloji laboratuvarı, tedavi ve enfeksiyon kontrolündeki rolleri, Mikrobiyol Bült 2005;39(2):229-40
  7. Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN: Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates, Diagn Microbiol Infect Dis 2005;52(3):209-13
  8. Gales AC, Jones RN: Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates, Diagn Microbiol Infect Dis 2000;36(1):19-36
  9. Gültekin M, Öğünç D, Günseren F, Çolak D, Kırbaş İ, Mamıkoğlu L: Hastane infeksiyonu etkeni Klebsiella pneumoniae ve Escherichia coli suşlarının genişlemiş spektrumlu beta-laktamaz ve antibiyotik duyarlılık özelliklerinin araştırılması, İnfeksiyon Derg 1999;13(4):515-20
  10. Gür D: Genişlemiş spektrumlu beta-laktamazlar, “Ulusoy S (ed): Betalaktamazlar ve Klinik Önemi” kitabında s. 70, Bilimsel Tıp Yayınevi, İzmir (2005)
  11. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST Program) Group: In vitro activity of tigecycline against 6792 Gram-negative and Grampositive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004), Diagn Microbiol Infect Dis 2005;52(3):215-27
  12. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse JE: The pharmacokinetic and p